Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to confirm efficacy and safety when administering lamivudine tablet alone in subjects with hepatitis B virus-induced liver cirrhosis.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Lamivudine

Criteria

Inclusion Criteria:

• Subjects with hepatitis B virus-induced liver cirrhosis, in whom lamivudine tablet was administered alone for 6 months or longer, or those in whom lamivudine tablet was expected to be administered alone for 6 months or longer

Exclusion Criteria:

• Subjects previously enrolled in Drug Use Investigation or Special Drug Use Investigation of lamivudine tablet

• Subjects with a history of hypersensitivity of the ingredients of lamivudine tablet